After years of volatility, Prudential shows a promising inflection with a 153.7% TTM revenue growth and a 92.1% combined ratio in 2026Q2, but the extreme swings in EPS (from -87.2% to +190.9%) indicate these results remain distorted by non-recurring accounting or market factors.
Prudential plc (PUK) annual income statement — 26-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 |
|---|
| Revenue | 44.35B | 20.65B | 8.14B | 11.97B | -27.59B | 26.5B | 36.25B | 70.76B | 20.93B | 65.12B | 58.41B | 27.95B | 37.44B | 32.22B | 87.97B | 55.1B | 47.65B | 48.1B | -10.27B | 65.19B | 68.63B | 41.13B | 65.03B | 30.14B | 6.65B | 7.5B | 13.48B |
| Revenue Growth % | 153.23% | 153.68% | -32.01% | 143.39% | -204.11% | -26.89% | -48.77% | 238.14% | -67.86% | 11.49% | 108.97% | -25.34% | 16.19% | -63.37% | 59.64% | 15.65% | -0.94% | 568.48% | -115.75% | -5.02% | 66.89% | -36.76% | 115.79% | 353.02% | -11.33% | -44.33% | - |
| Medical Costs & Claims | 4.39B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7.19B | -21.27B | -13.31B | -13.35B | -22.68B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Medical Cost Ratio % | 9.89% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -34.36% | -32.67% | -22.78% | -47.77% | -60.59% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Gross Profit | 27.29B | 20.65B | 8.14B | 11.97B | -27.59B | 26.5B | 36.25B | 70.76B | 28.12B | 86.39B | 71.72B | 41.3B | 60.13B | 32.22B | 87.97B | 55.1B | 47.65B | 48.1B | -10.27B | 65.19B | 68.63B | 41.13B | 65.03B | 30.14B | 6.65B | 7.5B | 13.48B |
| Gross Margin % | 61.52% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 134.36% | 132.67% | 122.78% | 147.77% | 160.59% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | - | 153.68% | -32.01% | 143.39% | -204.11% | -26.89% | -48.77% | 151.66% | -67.45% | 20.46% | 73.63% | -31.3% | 86.59% | -63.37% | 59.64% | 15.65% | -0.94% | 568.48% | -115.75% | -5.02% | 66.89% | -36.76% | 115.79% | 353.02% | -11.33% | -44.33% | - |
| Operating Expenses | 18.32B | 16.97B | 5.19B | 9.87B | -26.95B | 23.82B | 36.25B | 3.79B | 2.26B | 4.68B | 4.4B | 3.21B | 2.79B | 2.65B | 87.97B | 55.1B | 73.54B | 77.78B | 2.38B | 65.19B | 68.63B | 68.85B | 65.03B | 30.14B | 6.65B | 7.5B | 13.48B |
| OpEx / Revenue % | 41.31% | 82.2% | 63.72% | 82.48% | 97.67% | 89.9% | 100% | 5.35% | 10.82% | 7.19% | 7.53% | 11.49% | 7.46% | 8.22% | 100% | 100% | 154.34% | 161.7% | -23.2% | 100% | 100% | 167.4% | 100% | 100% | 100% | 100% | 100% |
| Depreciation & Amortization | -8.7B | 0 | -191M | 524M | 0 | 0 | 218M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.3B | -120M | 462.25M | 655.36M | 539.58M | 591.37M | 404.77M |
| Combined Ratio % | 51.19% | 82.2% | 63.72% | 82.48% | 97.67% | 89.9% | 100% | 5.35% | -23.55% | -25.48% | -15.26% | -36.28% | -53.13% | 8.22% | 100% | 100% | 154.34% | 161.7% | -23.2% | 100% | 100% | 167.4% | 100% | 100% | 100% | 100% | 100% |
| Operating Income | 17.02B | 3.68B | 2.95B | 2.1B | -643M | 2.68B | 3.03B | 66.97B | 18.66B | 60.44B | 54.01B | 24.74B | 34.65B | 29.58B | 3.19B | 1.19B | 2.07B | 1.56B | -2.07B | 1.19B | 2.07B | 2.47B | 1.75B | 0 | 0 | 0 | 0 |
| Operating Margin % | 38.38% | 17.8% | 36.28% | 17.52% | 2.33% | 10.1% | 8.36% | 94.65% | 89.18% | 92.81% | 92.47% | 88.51% | 92.54% | 91.78% | 3.62% | 2.15% | 4.35% | 3.25% | 20.2% | 1.82% | 3.02% | 6.01% | 2.69% | 0% | 0% | 0% | 0% |
| Operating Income Growth % | - | 24.47% | 40.82% | 426.13% | -124.03% | -11.72% | -95.47% | 258.84% | -69.12% | 11.9% | 118.32% | -28.6% | 17.15% | 827.73% | 168.58% | -42.71% | 32.48% | 175.41% | -275.02% | -42.78% | -16.26% | 41.48% | - | - | - | - | - |
| EBITDA | 8.47B | 3.81B | 2.76B | 2.62B | -233.86M | 3B | 3.25B | 66.97B | 18.66B | 60.44B | 54.01B | 24.74B | 34.65B | 29.58B | 3.26B | 2.21B | 2.33B | 1.77B | -1.9B | 1.23B | -225M | 2.35B | 2.21B | 0 | 0 | 0 | 0 |
| EBITDA Margin % | 19.1% | 18.46% | 33.94% | 21.9% | 0.85% | 11.34% | 8.96% | 94.65% | 89.18% | 92.81% | 92.47% | 88.51% | 92.54% | 91.78% | 3.71% | 4.01% | 4.89% | 3.69% | 18.53% | 1.88% | -0.33% | 5.72% | 3.4% | 0% | 0% | 0% | 0% |
| Interest Expense | 340.76M | 136.13M | 171M | 172M | 200M | 328M | 316M | 496M | 547M | 574.35M | 444.17M | 462.23M | 530.76M | 502.94M | 452.48M | 444.04M | 396.65M | 337.95M | 251.88M | 333.17M | 346.78M | 301.12M | 187M | 0 | 0 | 0 | 0 |
| Non-Operating Income | -5.54B | -136.13M | -171M | -438M | -200M | -328M | 30.23M | 111.31M | -6.33B | -17.1B | 50.76B | -11.27B | 30.05B | -16.83B | -74M | -1.02B | -257M | -209M | -172M | -41M | -327M | 120M | 113M | 655.36M | 539.58M | 591.37M | 404.77M |
| Pretax Income | 7.48B | 3.68B | 2.95B | 2.1B | -643M | 2.68B | 2.91B | 1.73B | 3.45B | 4.45B | 2.81B | 4.66B | 4.07B | 2.7B | 4.44B | 2.9B | 3.2B | 2.53B | -3.04B | 2.1B | 4.35B | 3.62B | 2.99B | 1.83B | -1.67B | -1.05B | 0 |
| Pretax Margin % | 16.87% | 17.8% | 36.28% | 17.52% | 2.33% | 10.1% | 8.02% | 2.44% | 16.49% | 6.84% | 4.81% | 16.69% | 10.87% | 8.37% | 5.05% | 5.26% | 6.71% | 5.26% | 29.58% | 3.22% | 6.34% | 8.79% | 4.6% | 6.06% | -25.11% | -13.96% | 0% |
| Income Tax | 1.29B | 611.48M | 538M | 385M | 354M | 462M | 440M | 252.13M | 569M | 1.22B | 436.77M | 842.98M | 619.47M | 476.56M | 954M | 644.33M | 981.6M | 1.41B | -2.46B | 692.12M | 2.43B | 2.39B | 1.82B | 1.55B | 71.04M | -1.35B | 0 |
| Effective Tax Rate % | 17.27% | 16.64% | 18.22% | 18.36% | -55.05% | 17.26% | 15.13% | 14.6% | 16.49% | 27.49% | 15.56% | 18.07% | 15.23% | 17.68% | 21.49% | 22.24% | 30.69% | 55.82% | 81.15% | 32.99% | 55.88% | 66.11% | 60.92% | 84.65% | -4.25% | 129.13% | - |
| Net Income | 6.38B | 2.96B | 2.29B | 1.7B | -1.01B | -2.04B | 2.12B | 591.08M | 3.15B | 2.39B | 2.37B | 3.82B | 3.45B | 2.22B | 2.16B | 1.49B | 1.43B | 1.09B | -579.91M | 1.88B | 1.71B | 1.29B | 991.64M | 1.19B | 724.36M | -592.83M | 0 |
| Net Margin % | 14.39% | 14.33% | 28.07% | 14.21% | 3.65% | -7.71% | 5.84% | 0.84% | 15.07% | 3.67% | 4.06% | 13.67% | 9.21% | 6.89% | 2.46% | 2.7% | 3% | 2.27% | 5.65% | 2.88% | 2.49% | 3.13% | 1.52% | 3.94% | 10.89% | -7.9% | 0% |
| Net Income Growth % | 245.73% | 29.51% | 34.33% | 268.92% | 50.69% | -196.41% | 258.33% | -81.25% | 31.96% | 0.8% | -37.97% | 10.78% | 55.4% | 2.61% | 45.17% | 4.12% | 30.91% | 288.49% | -130.88% | 9.68% | 33.04% | 29.79% | -16.49% | 63.94% | 222.19% | - | - |
| EPS (Diluted) | 5.05 | 2.28 | 1.68 | 2.48 | -1.48 | -3.10 | 3.26 | 1.14 | 1.30 | 1.40 | 1.22 | 1.36 | 1.08 | 0.66 | 1.70 | 1.18 | 1.14 | 0.54 | -0.32 | 0.78 | 0.72 | 0.64 | 0.48 | 0.00 | 0.00 | 0.00 | 1.46 |
| EPS Growth % | 237.98% | 35.71% | -32.26% | 267.57% | 52.26% | -195.09% | 185.96% | -12.31% | -7.14% | 14.75% | -10.29% | 25.93% | 63.64% | -61.18% | 44.07% | 3.51% | 111.11% | 268.75% | -141.03% | 8.33% | 12.5% | 33.33% | - | - | - | -100% | - |
| EPS (Basic) | - | 2.30 | 1.68 | 2.48 | -1.48 | -3.10 | 3.26 | 1.14 | 1.30 | 1.40 | 1.22 | 1.36 | 1.08 | 0.66 | 1.70 | 1.18 | 1.14 | 0.54 | -0.32 | 0.78 | 0.72 | 0.64 | 0.48 | 0.00 | 0.00 | 0.00 | 1.48 |
| Diluted Shares Outstanding | 1.26B | 1.29B | 1.36B | 686.75M | 684M | 657M | 649.25M | 1.29B | 1.29B | 1.28B | 1.28B | 1.28B | 1.28B | 1.28B | 1.27B | 1.27B | 1.26B | 1.25B | 1.24B | 1.22B | 1.21B | 1.18B | 1.06B | 0 | 0 | 0 | 511.91M |
Quick answers to the most common questions about buying PUK stock.
For fiscal year 2025, Prudential plc (PUK) reported total revenue of $20.65B. This represents a 53.2% increase compared to $13.48B in 2000.
Prudential plc (PUK) is profitable, generating $2.96B in net income for the fiscal year ending 2025 with a net profit margin of 14.3%.
Prudential plc (PUK) reported an operating income of $3.68B, resulting in an operating profit margin of 17.8%. This margin reflects the operational efficiency of the business before interest and taxes.
Prudential plc (PUK) generated $20.65B in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Revenue Volatility and Accounting Complexity
Revenue Surge Masks Underlying Volatility
Prudential's revenue grew 153.7% year-over-year for the TTM period, an extraordinary pace driven by market recovery and a normalizing Hong Kong-Mainland corridor, though such magnitude raises questions about sustainability.
The trajectory is not a steady climb but a series of sharp oscillations, from -77.4% growth in 2022Q2 to +123.2% in 2023Q2, and now +110.5% in 2025Q4. This pattern suggests the business is highly sensitive to external catalysts like border reopenings and market sentiment, making the current acceleration potentially cyclical rather than structural. Investors should monitor whether this growth is expanding the recurring premium base or is concentrated in lumpy savings and investment-linked products.
Underwriting Profitability Emerges in Latest Quarter
In 2026Q2, Prudential reported a combined ratio of 92.1%, its first quantifiable underwriting profit in the dataset, indicating a favorable shift in its insurance operations' cost structure.
The 92.1% combined ratio, derived from a 29.4% loss ratio, is a positive signal for core profitability, as it implies the company is earning an underwriting margin before investment returns. However, the lack of comparable historical data in the provided quarters makes it difficult to assess if this represents a new, sustainable trend or a one-off favorable development. The operating margin of 17.8% mentioned in the company intelligence appears modest, suggesting that scale and expense management remain critical to translating underwriting results into bottom-line profit.
Inconsistent Reporting Obscures Reserve Health
The data shows periods where claims/loss figures are reported as zero, which is inconsistent with a life insurer's operations and makes a direct analysis of reserve adequacy and development impossible from the provided statements.
For a life and health insurer, claims and benefits are the primary cost of doing business. The reporting of $0 claims in multiple quarters, such as 2025Q4 and 2025Q2, either reflects a specific accounting presentation under IFRS 17 or missing data. This obscures whether current earnings are being inflated by reserve releases from prior years or if the company is facing an unreported increase in claim frequency. Without consistent loss data, any assessment of the quality and sustainability of Prudential's reported profit is significantly hampered.
The 2025-2026 Recovery Phase
The period from 2025Q4 through 2026Q2 marks a dramatic inflection, with revenue accelerating from $11.3B to $14.9B and a transition from negligible claims to a visible underwriting profit.
This inflection appears to be the most significant operational shift in the dataset, coinciding with the reopening of key Asian markets and the full implementation of new accounting standards. The jump from an $8.1B operating income in 2025Q2 to a more normalized $1.2B in 2026Q2 warrants investigation, as it may indicate that the prior period included large, non-recurring items. The key question for the market is whether this inflection point represents a new, higher baseline of profitability or a temporary peak in the cycle.
Earnings Quality vs. Accounting Noise
Prudential's reported revenue and profit swings are extreme, with EPS growth ranging from -87.2% to +190.9%, suggesting that headline figures may be heavily distorted by investment market volatility and IFRS 17 implementation effects.
The most challenging aspect for an analyst is reconciling the wildly fluctuating EPS and revenue with the presumed stability of a large life insurer's in-force book. The near-200% EPS growth in 2024Q4 and subsequent declines imply earnings are not yet driven by stable, recurring premium income but by market-sensitive elements. This forces reliance on adjusted operating profit, but even that metric shows volatility. The risk is that the market is pricing in a smooth, upward trajectory based on recent highs, while the underlying earnings power remains unproven and susceptible to medical inflation, regulatory changes, and capital market corrections.